Loading stock data…
Travere Therapeutics, Inc. (TVTX)
$66.07+0.79 (+1.21%)
Market ClosedLast close Sep 8
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Travere Therapeutics, Inc. in the Healthcare sector is trading at $66.07 with a market capitalization of $5.9B. Wall Street consensus targets $74.21 (14 analysts), implying a +12.3% move over the next 12 months. The stock is currently near its 52-week high of $68.03, remaining 55.2% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +12.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $169.58M↑ | $127.20M↓ | $129.69M↓ | $164.86M↑ | $114.45M |
| Gross Profit | $160.35M↑ | $100.43M↓ | $127.14M↓ | $163.27M↑ | $99.29M |
| Operating Income | $3.95M↑ | -$36.91M↓ | -$32.43M↓ | $24.93M↑ | -$12.65M |
| Net Income | -$34.80M↑ | -$37.10M↓ | $2.73M↓ | $25.71M↑ | -$12.76M |
Peer Comparison
JNJUNHPFE
Fundamentals
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, o...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.86B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.04
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-177.24%
Volume
Today's trading volume
1.36M
Recent News
Travere Therapeutics' Outlook Brightens As Turnaround Looms
Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers near a buy zone.
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book
On August 6, Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results showing royalty revenue up 32% year over year, just weeks after the company closed its acquisition of XOMA Royalty. Total revenue reached $63.7 million for the quarter, up from $47.6 million a year earlier, and Ligand raised the low end of its full-year adjusted earnings […]
TGTX Stock Outperforms 95% of Stocks. Here's Why.
Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average.
IBD Stock Of The Day, Travere Therapeutics, Tests Another Breakout. Can The Stock Get Any 'Sweeter?'
Travere Therapeutics is Friday's IBD Stock Of The Day. As the Filspari story gets "sweeter," shares are clearing a fresh buy point.
Three Biotech Stocks Stick Out With Their Stellar Charts
These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.